Overview

Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension

Status:
NOT_YET_RECRUITING
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study has been designed to assess the safety, tolerability, and pharmacokinetics of a therapeutic dose of hydrocodone bitartrate with and without an oral dose of doxapram hydrochloride in healthy volunteers who are naltrexone-blocked.
Phase:
PHASE1
Details
Lead Sponsor:
Quivive Pharma, Inc.
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Doxapram
Hydrocodone